Sanofi-Aventis has acquired Zentiva N.V.
Sanofi-Aventis has successfully completed and settled the voluntary tender offer for all of Zentiva N.V.'s shares. Total value of this transaction is over US$2 billion.
Sanofi-Aventis, a leading global pharmaceutical company, discovers, develops and distributes a broad offering of medicines, vaccines and integrated healthcare solutions adapted to local needs and means. Sanofi-Aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Zentiva N.V. is an international pharmaceutical company focused on developing, manufacturing and marketing modern generic pharmaceutical products. The company has leading positions in the pharmaceutical markets in the Czech Republic, Slovakia, Romania and Turkey, and is growing rapidly in Poland, Russia, Bulgaria, Hungary, the Ukraine and the Baltic States.
Oaklins' team in the Czech Republic acted as the tender agent to Sanofi-Aventis in relation to the voluntary tender offer for all of Zentiva N.V.'s shares. From July 2008 to March 2009, the Czech team arranged the purchase of approximately 70% of the issued share capital of Zentiva.


Talk to the deal team
Related deals
Pharma-Skan & Skan-Medic have been acquired by Brygge Partners
Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.
Learn moreThe Canton of Solothurn had a valuation report prepared for its hospitals
The Canton of Solothurn is the owner of Solothurner Spitäler AG (soH), with its three hospitals in Solothurn, Olten and Dornach.
Learn moreGenerali has expanded its footprint in Bulgaria by acquiring one of the top health insurers on the market
Doverie United Holding has successfully completed the sale of United Health Insurance Fund Doverie (Doverie) to Generali CEE Holding.
Learn more